Lawyers USA Your Business Partner

Glaxo, U.S. reach tentative $3B deal over Avandia 

Published: November 17, 2011

Tags: Avandia, Department of Justice, diabetes, drug litigation, GlaxoSmithKline, off-label uses

GlaxoSmithKline has announced a tentative deal with the federal government under which the drug company would pay a record $3 billion to end an investigation into the marketing of Avandia for “off-label” uses.

Former GlaxoSmithKline lawyer acquitted of all charges 

Published: May 10, 2011

Tags: FDA, Food and Drug Administration, GlaxoSmithKline, off-label uses, Wellbutrin

A federal judge in Greenbelt, Md. has acquitted a former GlaxoSmithKline lawyer accused of lying to the government about off-label marketing of one of the pharmaceutical company’s drugs.

Insurers can’t sue over ‘off-label’ Seroquel scripts 

By: Pat Murphy
Published: March 14, 2011

Tags: AstraZeneca, FDA, Food and Drug Administration, off-label uses, Seroquel

Health insurance plans cannot sue a pharmaceutical company to recover the cost of prescriptions written for the “off-label” use of its anti-psychotic drug, the 11th Circuit has ruled in affirming dismissals.

Dilantin lawsuits turn into a mini mass tort 

By: Sylvia Hsieh
Published: February 7, 2011

Tags: Dilantin, drug litigation, epilepsy, FDA, Food and Drug Administration, Mylan, off-label uses, Pfizer, phenytoin, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis

Litigation over the anti-seizure drug Dilantin has developed into a smaller-scale mass tort, with dozens of suits claiming that it causes horrendous and life-threatening skin burns.

Heart stent claims not completely preempted 

By: Pat Murphy
Published: August 3, 2010

Tags: failure to warn, medical devices, off-label uses, preemption, product liability, Riegel v. Medtronic

Federal medical device law does not completely preempt product liability claims over a coronary stent, the New Jersey Appellate Division has ruled in reversing a dismissal.

Pfizer settles Neurontin wrongful death suit 

By: Nora Tooher
Published: May 18, 2010

Tags: Neurontin, off-label uses, Pfizer, wrongful death

A settlement has been reached in the third Neurontin wrongful death case, which was scheduled to begin trial Tuesday in U.S. District Court in Nashville, Tenn.

Jurors in Neurontin trial hear opening arguments 

By: Nora Tooher
Published: March 31, 2010

Tags: Neurontin, off-label uses, Pfizer

BOSTON – Plaintiffs’ lawyer Ronald Rosenkranz urged jurors Wednesday to hold Pfizer Inc. liable for the death of Hartley Shearer, who committed suicide in 2002 after taking Neurontin for 16 months.

Jury selection begins in Neurontin suicide trial 

By: Nora Tooher
Published: March 29, 2010

Tags: Neurontin, off-label uses, Pfizer

BOSTON – Jury selection began Monday in the second wrongful death trial alleging Pfizer’s off-label promotion of its anti-epilepsy drug Neurontin caused a patient to commit suicide.

Pfizer ordered to pay $142M for Neurontin marketing fraud 

By: Nora Tooher
Published: March 26, 2010

Tags: Kaiser, Neurontin, off-label uses, Pfizer

BOSTON – A federal jury Thursday found that Pfizer violated anti-racketeering laws in promoting its epilepsy drug Neurontin for unapproved uses and must pay at least $142 million in damages.

Drug litigation preview 

By: Nora Tooher
Published: January 14, 2010

Tags: Avandia, Botox, Digitek, drug litigation, FDA, Food and Drug Administration, hormone replacement therapy, Neurontin, off-label uses, preemption, Prempro, Vioxx, whistleblower, Wyeth v. Levine

Plaintiffs’ lawyers are gearing up for a slew of pharmaceutical product liability trials in 2010.

While no case has the magnitude of the massive $4.85 billion Vioxx settlement in 2007, the trials represent a welcome return to courtroom action on the pharmaceutical front for plaintiffs’ lawyers.